Company: NCEL
Filing Date: 2025-10-17
Form Type: POS AM
Source: 0001213900-25-099986
Chunk: 79

Company: NewcelX Ltd.
Filing Date: 2025-10-17
Form: POS AM
Chunk 79
---
 1,273 |   |
| Reserve from share-based payment transactions           |     |      918 |      |     |     546 |         |     |          452 |   |
| Reserve from transactions with controlling shareholders |     |    4,303 |      |     |   4,013 |         |     |        4,105 |   |
| Foreign currency translation reserve                    |     |   (2,040 | )    |     |    (941 | )       |     |       (1,094 | ) |
| Accumulated deficit                                     |     |  (87,734 | )    |     | (70,582 | )       |     |      (76,530 | ) |
| Total equity                                            |     |  (15,081 | )    |     |  (2,167 | )       |     |       (7,996 | ) |
| Total liabilities and equity                            |     |      461 |      |     |   1,430 |         |     |          903 |   |

____________ (*)Less than $1. The accompanying notes are an integral part of the interim financial statements.

| August 31, 2025                              |     |                                                     |     |            |     |                       |
|:---------------------------------------------|:----|:----------------------------------------------------|:----|:-----------|:----|:----------------------|
| Date of approval of the financial statements |     | Ronen Twito CEO and Executive Chairman of the Board |     | Liora Oren 
 Director   |     | Uri Ben Or            
 Chief Finance Officer |

Annex B-2

KADIMASTEM LTD.
STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE LOSS

| 2025                                                                                                                   |     | Six months ended 
          June 30 | 2024 |     |       |         |     |   Year ended 
 December 31, 
         2024 |   |
|:-----------------------------------------------------------------------------------------------------------------------|:----|-----------------:|:-----|:----|------:|:--------|:----|-------------:|:--|
| Unaudited                                                                                                              |     |                  |      |     |       | Audited |     |              |   |
| USD in thousands (except per share data)                                                                               |     |                  |      |     |       |         |     |              |   |
| Research and development expenses, net                                                                                 |     |              576